New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 3, 2018 - Ocular Therapeutix announced the FDA approval of Dextenza (dexamethasone ophthalmic insert), for the treatment of ocular pain following ophthalmic surgery.
Download PDF
Return to publications
